OncoHost has raised $35 million in a series C funding round to launch its PROphet blood test, a machine learning-based host response profiling platform currently being evaluated in clinical trials.
The new funding will go toward expanding the multicenter trial and support U.S. commercial development of the platform, the company said in a release.
PROphet provides early identification of an individual's responsiveness to cancer therapy, analysis of treatment resistance mechanisms, and potential available strategies to overcome this resistance, OncoHost said.
The funding round was led by Alive Israel HealthTech. Other investors included Israeli financial firm Leumi Partners, Israel's largest pension fund Menora Mivtachim, and OurCrowd.